MarketVIEW: Clostridium difficile VaccinesVacZine AnalyticsAugust 1, 2008 34 Pages - SKU: VZAN1833520 |
| As well as new small molecule approaches, commercial manufacturers are also pursuing immunologic strategies to prevent and/or manage infections caused by the hospital “superbug”, Clostridium difficile (C.diff). This MarketVIEW product is a comprehensive Excel-based model forecasting the potential commercial value of a prophylactic C.diff vaccine across the seven major markets. The model contains value ($ m) and volume (mio doses) estimates in both community and hospitalized populations along with predictions of launch timeframe and future competitive environment(s). Use of the new vaccine in a therapeutic setting (prevention of relapses) is also included using estimations of disease incidence. The model tabulates all included assumptions and is easily adjusted with client modifications.
Please Note: This is delivered as a excel file. |
Related Markets
Vaccines Reports
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Lung Cancer, Cancer Vaccines and Protein Kinase Inhibitors
